References

  1. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths and prevalence-United States, 1996. MMWR. 1997; 46(8):165-173. This article on PubMed

  2. Morlat P. Chronicité de l’infection par le VIH. Rev Prat. 1999; 49(16): 1781-1785. This article on PubMed

  3. Ankri J, Le Disert D, Henrard JC. Comportements individuels face aux médicaments: de l'observance thérapeutique à l'expérience de la maladie, analyse de la littérature. Santé Publique. 1995; 7(12) : 427-441

  4. Montaner J, Hogg R, Yip B, Wood E, Harrigan R, O'Shaughnessy J. Further characterizing determinants of disease progression among HIV-1 infected patients initiating triple drug therapy. IAS Conf HIV Pathog Treat. 2001 Jul 8-11; 1st: Abstract No LB-O10

  5. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997; 11: 113-116. This article on PubMed

  6. Le Moing V, Chene G, Carrieri MP, Besnier JM, Masquelier B, Salamon R et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr. 2001; 27(4):372-376. This article on PubMed

  7. UNAIDS. Treatment, care and support for people living with HIV. Report on the global AIDS epidemic 2004. Available from: URL: http://www.unaids.org/bangkok2004/gar2004_html/GAR2004_08_en.htm#P999_205335. Accessed 10 january 2012

  8. de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS. 1997 Sep;11(11):F79-84. This article on PubMed

  9. Mouala C, Roux P, Okome M, Sentenac S, et al. Assessment of compliance with ARV treatment in Africa. Med Trop (Mars). 2006 Dec;66(6):610-4. This article on PubMed

  10. Delfraissy JG. Prise en charge des personnes infectées par le VIH : Recommandations du groupe d’experts. Paris: Flammarion Médecine-Sciences; 2002. p 384

  11. Paterson D, Swindells S, Mohr J, Brester M et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1): 21-30. This article on PubMed

  12. Bintou D, Aliou S, Ousmane T, Noumousso M. Observance thérapeutique des patients sous ARV, expérience du CESAC de Bamako au Mali. Développement et Santé. 2004; 172(Hors série): 15-18

  13. Frenkel L, Mullins J. Should patients with drug resistant HIV-1 continue to receive antiretroviral therapy?. N Engl J Med. 2001; 344(7): 520-22. This article on PubMed

  14. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 26(5):435-442. This article on PubMed

  15. Badré-Sentenac S, Essomba C, Commeyras C, Kouanfack C, Rey JL. Utilisation du renouvellement des ordonnances d’antirétroviraux comme indicateur d’observance à Yaoundé. J Pharm Clin. 2005; 24 (4) : 225-31

  16. Orrell C, Wood R. Initial data on antiretroviral adherence in Cape Town, South Africa. IAS Conf HIV Pathog Treat. 2001 Jul 8-11;1st: Abstract No 696

  17. Lanièce I, Ciss M, Desclaux A, Diop K, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003 Jul;17 Suppl 3:S103-8. This article on PubMed

  18. Base de données pays OMS (WHOSIS). Available from http://www.who.int/whosis/en/. Accessed Accessed 10 january 2012

  19. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996 Dec 25;276(24):1955-6. This article on PubMed

  20. ONUSIDA. Rapport sur l’épidémie mondial du SIDA 2010. Available at http://data.unaids.org/pub/GlobalReport/2010/2010_GR_CH02_fr.pdf. Accessed Accessed 10 january 2012

  21. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84. This article on PubMed

  22. Oumar AA, Dao S, Diamoutene A, Coulibaly S, et al. Factors associated with antiretroviaral treatment observance at Point "G" hospital. Mali Med. 2007;22(1):18-21. This article on PubMed

  23. Abellan J, Garotte M, Saiz-Maza M et al. Triple therapy adherence in HIV positive patients - Proceedings of the 4th congress in drug therapy-HIV infect. AIDS. 1998; 12 (4)

  24. Sow K, Desclaux A. L'adhésion au traitement antirétroviral. In : Desclaux A, Lanièce, Ndoye I, Taverne B. L'initiative sénégalaise d'accès aux antirétroviraux. Analyses économiques, sociales, comportementales et médicales. Paris : ANRS, Collections Sciences Sociales et SIDA. 2002: 129-139

  25. Landman R, Schieman R, Thiam S, Vray M, Canestri A, Mboup S et al. Once -a- day highly active antiretroviral therapy in treatment naïve HIV-1 infected adults in Sénégal. AIDS. 2003; 17 (7) : 1017-1022. This article on PubMed

  26. Laurent C, Diakhaté N, Ngom Gueye NF, Touré MA, Sow PS, Faye MA et al. The Senegalese government's HAART initiative: a 18-month follow up study of feasibility, effectiveness, adherence, toxicity and viral resistance. AIDS. 2002; 16 (10) : 1363-1370. This article on PubMed

  27. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003 Nov-Dec;11(6):185-98. This article on PubMed

  28. Garcia R, Schooley RT, Badaró R. An adherence trilogy is essential for long-term HAART success. Braz J Infect Dis. 2003 Oct;7(5):307-14. This article on PubMed

  29. Hosseinipour MC, Kazembe PN, Sanne IM, van der Horst CM. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002;16 Suppl 4:S177-87. This article on PubMed

  30. Moulin P. Enquête sur les pratiques des professionnels de santé en matière d’observance dans le domaine du VIH/SIDA en France : Recherches, actions, évaluations. In : L'observance aux traitements contre le VIH/SIDA : Mesures, déterminants, évolution. Paris: ANRS, Collections Sciences Sociales et SIDA; 2001. pp 21-31

  31. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Read. 2000 Mar;10(3):177-85. This article on PubMed

  32. Costagliola D, Barberousse C. Comment mesurer l'observance. In L'observance aux traitements contre le VIH/SIDA. Paris : ANRS, Collection Sciences sociales et SIDA; 2001. p 33-42

  33. Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000; 24(2):123-128. This article on PubMed

  34. Duran S, Solas C, Spire B, et al. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients’self- reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS. 2001; 15:1075-1077. This article on PubMed

&nb